Core Points - Guizhou Bailing's stock price dropped by 6.77% today, with a turnover rate of 12.01% and a trading volume of 9.17 billion yuan, showing a fluctuation of 8.59% [2] - Institutional investors net sold 21.42 million yuan, while the Shenzhen Stock Connect recorded a net sell of 2.45 million yuan [2] - The stock was listed on the Shenzhen Stock Exchange for a daily decline deviation of -7.54%, with institutional proprietary seats net selling 21.42 million yuan [2] Trading Data - The top five trading departments had a total transaction amount of 232 million yuan, with a buying amount of 104 million yuan and a selling amount of 128 million yuan, resulting in a net sell of 23.77 million yuan [2] - Among the trading departments, two institutional proprietary seats were involved, with a total buying amount of 15.40 million yuan and a selling amount of 36.82 million yuan, leading to a net sell of 21.42 million yuan [2] - The main fund flow showed a net outflow of 6.24 million yuan, with a large single net outflow of 16.39 million yuan and a large single net inflow of 10.15 million yuan. Over the past five days, the main fund net inflow was 61.82 million yuan [2]

每经AI快讯，有投资者在投资者互动平台提问：请问一下，贵公司2025上半年业绩什么时候公布？ 贵州百灵（002424.SZ）8月5日在投资者互动平台表示，公司2025年半年报预约2025年08月20日披露。 （文章来源：每日经济新闻） ...

Core Viewpoint - The research paper on the clinical efficacy and safety of "Tangening Tongluo Tablets combined with Tangening Tongluo Ointment for Type 2 Diabetic Foot Ulcers" has been published, indicating significant healing effects and clinical value for diabetic foot patients [1] Group 1 - The study was led by Professor Gu Yunjuan from Nantong University Affiliated Hospital and was sponsored by Guizhou Bailing [1] - Results show that both Tangening Tongluo Tablets and Ointment significantly promote the healing of diabetic foot ulcers [1] - The combined treatment demonstrates superior long-term effects, enhancing local immunity, inhibiting bacterial growth, and reducing infection risks [1] Group 2 - The research improves the clinical prognosis for diabetic foot patients, highlighting its high clinical application value [1]

Group 1 - The stock of Aonlikang is approaching a limit down, indicating significant selling pressure [1] - Several pharmaceutical companies, including Nanjing New Pharmaceutical, Huason Pharmaceutical, Yuekang Pharmaceutical, Chenxin Pharmaceutical, Guizhou Bailing, and Shutaishen, have all experienced declines exceeding 6% [1]

Group 1 - Guizhou Bailing's stock price closed at 6.65 yuan on August 4, 2025, up 1.84% from the previous trading day [1] - The stock opened at 6.83 yuan, reached a high of 6.94 yuan, and a low of 6.28 yuan, with an intraday volatility of 10.11% [1] - The trading volume was 2.368 million hands, with a total transaction amount of 1.57 billion yuan [1] Group 2 - Guizhou Bailing specializes in the production and sales of traditional Chinese medicine, with key products including Kesu Ting syrup and Yindan Xinnao Tong soft capsules [1] - The company is located in Anshun City, Guizhou Province, and is recognized as a key pharmaceutical enterprise in the region [1] Group 3 - On August 4, the stock experienced rapid fluctuations, with a rebound of over 2% within 5 minutes around 9:40 AM, following a drop of over 2% earlier at 9:37 AM [1] - On the same day, the net outflow of main funds was 164 million yuan, accounting for 2.03% of the circulating market value [1] - Over the past five trading days, there was a cumulative net inflow of 54.5469 million yuan, representing 0.68% of the circulating market value [1]

A股中药板块高开，奇正藏药4连板，新天药业、太龙药业、贵州百灵、维康药业、康缘药业跟涨。 ...

000558 天府文旅 B004 000826 启迪环境 B001 000998 隆平高科 B001 001236 弘业期货 A07 001314 亿道信息 A06 001324 长青科技 A06 002037 保利联合 A06 002198 嘉应制药 A07 002219 新里程 B001 002330 得利斯 B007 002408 齐翔腾达 B003 002424 贵州百灵 A07 002600 领益智造 B007 002629 仁智股份 A07 002634 棒杰股份 A07 002716 湖南白银 A06 002775 文科股份 B004 002799 环球印务 A07 002921 联诚精密 A07 002940 昂利康 B004 002951 金时科技 A06 300691 联合光电 A06 301632 广东建科 A08 600009 上海机场 A08 600031 三一重工 A08 600104 上汽集团 A08 600166 福田汽车 B003 600507 方大特钢 B001 平安基金 B003 融通基金 B007 上银基金 B005 天弘基金 B006 太平基金 B005 信达证券基金 ...

Group 1 - The stock of Guizhou BaiLing has experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over two consecutive trading days (July 31, 2025, and August 1, 2025) [1] - The company's board of directors has verified that there are no undisclosed significant information or major matters that should have been disclosed during the period of stock fluctuation, and that the controlling shareholder and actual controller did not trade the company's stock during this time [1][3] - The board confirms that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange's listing rules, and that previous disclosures do not require correction or supplementation [1]

Market Performance - The two markets opened lower on Friday, with the Shanghai Composite Index closing at 3559.95 points, down 0.37%, and the Shenzhen Component down 0.17% [1] - The total trading volume was 15,984 billion, a significant decrease of 3,377 billion (-17.44%) compared to Thursday [1] - Over 80% of industry sectors saw gains, with warehousing logistics, construction decoration, software, paper printing, and ecological environment sectors leading the rise [1] Industry Highlights - The Chinese medicine sector experienced a significant surge, with Weikang Pharmaceutical hitting the 20% daily limit, alongside other companies like Tianmu Pharmaceutical and Guizhou Bailin also reaching the limit [1] - The photovoltaic sector also performed well, with Jiejia Weichuang and Shuangliang Energy both hitting the daily limit [1] Technical Analysis - The three major indices showed a volume contraction and closed with long upper shadows, indicating a potential reversal after five consecutive weeks of gains [2] - The Shanghai Composite, Shenzhen Component, and ChiNext Index fell by 0.94%, 1.58%, and 0.74% respectively for the week, with total trading volume at 8.93 trillion, down 1.76% from the previous week [2] Investment Strategy - Companies are advised to reduce positions in high-flying stocks that have seen significant gains, while looking to invest in undervalued small and mid-cap growth stocks that have shown strong performance in Q1 and exceeded expectations in H1 [2] - There is a recommendation to allocate some resources towards brokerage stocks in anticipation of the upcoming half-year and third-quarter earnings reports [2]

证券代码：002424 证券简称：贵州百灵 公告编号：2025-037 贵州百灵企业集团制药股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、股票交易异常波动的情况介绍 3、公司目前的经营情况及内外部经营环境未发生重大变化； 4、经核查，公司、控股股东和实际控制人不存在关于本公司的 应披露而未披露的重大事项，或处于筹划阶段的重大事项，股票异常 波动期间，公司控股股东、实际控制人未买卖公司股票； 5、公司不存在导致股票交易严重异常波动的未披露事项。 三、是否存在应披露而未披露信息的说明 公司董事会确认，公司目前没有任何根据《深圳证券交易所股票 上市规则》等有关规定应予以披露而未披露的事项或与该事项有关的 筹划、商谈、意向、协议等；董事会也未获悉本公司有根据《深圳证 券交易所股票上市规则》等有关规定应予以披露而未披露的、对本公 司股票及其衍生品种交易价格产生较大影响的信息；公司前期披露的 信息不存在需要更正、补充之处。 四、风险提示 贵州百灵企业集团制药股份有限公司（以下简称"公司"或"本 公司"）股票（证券简称：贵州百灵，证 ...